OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Hematology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Hematological findings and complications of COVID‐19	1221
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	314
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	235
Thrombosis in COVID‐19	222
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management	210
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management	187
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures	158
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management	144
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies	138
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine	127
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management	118
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis	115
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA	112
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy	106
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management	104
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study	93
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center	90
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine	89
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients	83
Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab	81
Critically ill COVID‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability	76
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring	76
Acute myeloid leukemia: 2021 update on risk‐stratification and management	73
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management	72
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management	70

Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY	69
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	68
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab	68
Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism	67
Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management	67
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation	63
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management	63
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma	63
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality	60
Recommendations for diagnosis and treatment of methemoglobinemia	56
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	53
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment	53
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1	52
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients	51
Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome	50
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life	50
Increased blood viscosity and red blood cell aggregation in patients with COVID‐19	50
Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction	50
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management	49
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments	49
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma	47
SARS‐CoV‐2 infection in beta thalassemia: Preliminary data from the Italian experience	47